(TYR1)-PTH (1-34) (HUMAN), with the CAS number 213779-10-3, is a synthetic peptide that represents the first 34 amino acids of human parathyroid hormone (PTH), modified to include a tyrosine substitution at the first position. This peptide plays a crucial role in calcium homeostasis and bone metabolism by mimicking the biological activity of natural PTH. It primarily acts on the parathyroid hormone receptor, stimulating osteoblast activity and promoting bone formation while also influencing renal tubular reabsorption of calcium and phosphate. The structural modification enhances its stability and bioactivity compared to the native hormone. (TYR1)-PTH (1-34) is utilized in research and therapeutic applications, particularly in the treatment of osteoporosis and other conditions related to bone density. Its pharmacokinetics, including absorption, distribution, metabolism, and excretion, are influenced by its peptide nature, which typically results in a shorter half-life compared to larger proteins. Overall, this compound exemplifies the intersection of biochemistry and therapeutic development in addressing metabolic bone diseases.

(TYR1)-PTH (1-34) (HUMAN)

213779-10-3: (TYR1)-PTH (1-34) (HUMAN), with the CAS number 213779-10-3, is a synthetic peptide that represents the first 34 amino acids of human parathyroid hormone (PTH), modified to include a tyrosine substitution at the first position. This peptide plays a crucial role in calcium homeostasis and bone metabolism by mimicking the biological activity of natural PTH. It primarily acts on the parathyroid hormone receptor, stimulating osteoblast activity and promoting bone formation while also influencing renal tubular reabsorption of calcium and phosphate. The structural modification enhances its stability and bioactivity compared to the native hormone. (TYR1)-PTH (1-34) is utilized in research and therapeutic applications, particularly in the treatment of osteoporosis and other conditions related to bone density. Its pharmacokinetics, including absorption, distribution, metabolism, and excretion, are influenced by its peptide nature, which typically results in a shorter half-life compared to larger proteins. Overall, this compound exemplifies the intersection of biochemistry and therapeutic development in addressing metabolic bone diseases.

(Tyr¹)-pTH (1-34) (human)

<p>Please enquire for more information about (Tyr1)-pTH (1-34) (human) trifluoroacetate salt including the price, delivery time and more detailed product information at the technical inquiry form on this page</p>

CAS 213779-10-3

(TYR1)-PTH (1-34) (HUMAN)

(Tyr¹)-pTH (1-34) (human)

Ref: 01-4031209

(Tyr1)-pTH (1-34) (human) trifluoroacetate salt

Ref: 3D-FT108877